What the FDA labels say about taking them together
Rifampin and suvorexant
Suvorexant's FDA label of March 10, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name suvorexant. The suvorexant label: “CYP3A Inducers Suvorexant exposure can be substantially decreased when co-administered with strong CYP3A inducers.”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the suvorexant FDA label on DailyMed (effective March 10, 2025, Merck Sharp & Dohme LLC).
What does the rifampin label say about suvorexant?
Rifampin's label (effective February 11, 2026) does not name suvorexant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the suvorexant label say about rifampin?
Suvorexant label, drug interactionsCYP3A Inducers Suvorexant exposure can be substantially decreased when co-administered with strong CYP3A inducers (e.g., rifampin, carbamazepine and phenytoin).
Source: FDA drug label (BELSOMRA), Merck Sharp & Dohme LLC, effective March 10, 2025 (SPL set e5b72731-1acb-45b7-9c13-290ad12d3951), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Suvorexant | |
|---|---|---|
| Labeled for | n/a | Insomnia |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | $15.21 per tablet 10 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once